Company: PSTV
Filing Date: 2025-08-04
Form Type: DRS
Source: 0000950123-25-006916
Chunk: 28

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-04
Form: DRS
Chunk 28
---
 of $0.46 per share of our common stock (which represents the closing price of our common stock on July 30, 2025) and the issuance of [1,612,903] shares of our common stock that are the Initial Commitment Shares to Lincoln Park for no cash consideration and after deducting estimated offering expenses payable by us, our as-adjustednet tangible book value as of June 30, 2025 would have been approximately $[●] million, or $[●] per share. This represents an immediate increase in net tangible book value of $[●] per share to existing stockholders and an immediate dilution of $[●] per share to new investors. The table below illustrates this per share dilution:

| Assumed offering price per share                                  
 Historical net tangible book value per share as of June 30, 2025  |     | $[●] 
 $[●] |
|:------------------------------------------------------------------|:----|:-----|
| Increase per share attributable to this offering                  |     | $[●] |
| As adjusted net tangible book value per share after this offering |     | $[●] |
| Dilution per share to new investors                               |     | $[●] |

The number of shares of common stock to be outstanding immediately after this offering in the table above is based on 92,180,007 shares outstanding as of June 30, 2025 and excludes, as of June 30, 2025:

| • |     | 1,230,272 shares of common stock issuable upon exercise of stock options outstanding under our equity incentive 
 plans, with a weighted-average exercise price of $3.79 per share;                                               |

| • |     | 76,025 shares of common stock reserved for future issuance under our 2015 New Employee Incentive Plan; |

| • |     | 47,742 shares of common stock reserved for future issuance under our 2020 Stock Incentive Plan; |

| • |     | 398 and 27,792 shares of common stock issuable upon conversion of 1,014 shares of Series B Convertible Preferred 
 Stock and 938 shares of Series C Preferred Stock, respectively; and                                              |

| • |     | 10,676,486 shares of common stock issuable upon exercise of pre-funded or 
 zero strike price warrants to purchase common stock; and                  |

| • |     | 3,883,833 shares of common